Sarepta Therapeutics (NASDAQ:SRPT) Reports Strong Preliminary Financial Results for 2024

Sarepta Therapeutics, Inc. recently disclosed certain preliminary financial information for the year ended December 31, 2024. During the 43rd Annual J.P. Morgan Healthcare Conference, Douglas S. Ingram, President, and Chief Executive Officer of the Company, revealed that as of December 31, 2024, the unaudited cash position stood at approximately $1.5 billion. Additionally, the Company reported approximately $1.79 billion in total net product revenue for the year and approximately $638 million in the fourth quarter of 2024.

The revenue was generated from sales of the Company’s four approved products, which include EXONDYS 51® (eteplirsen) Injection, VYONDYS 53® (golodirsen) Injection, AMONDYS 45® (casimersen) Injection, and ELEVIDYS. Notably, ELEVIDYS accounted for approximately $384 million in net product revenue in the fourth quarter of 2024 and $821 million for the full year.

The Company also underscored its commitment by issuing a press release on January 13, 2025, detailing the financial information disclosed. It’s crucial to note that the information revealed is preliminary and unaudited, subject to potential changes as the audit of the financial statements for the year ended December 31, 2024, progresses.

Sarepta Therapeutics reiterated its full-year 2025 guidance, expecting total net product revenue in the range of $2.9 to $3.1 billion. The Company expressed confidence in its financial outlook for the upcoming year, building on the robust performance observed in 2024.

While these preliminary results demonstrate a positive trend for Sarepta Therapeutics, the Company, like others in the industry, acknowledges the potential risks and uncertainties associated with the business. Sarepta emphasized the importance of risk factors and uncertainties, urging investors to consider the information provided in the Company’s regulatory filings, particularly under “Risk Factors” in their Quarterly Report on Form 10-Q for the quarter ended September 30, 2024, and other SEC filings.

Sarepta Therapeutics plans to present its final and complete financial results for the fourth quarter and full-year 2024 by late February 2025. The Company anticipates closing procedures for the year-ended December 31, 2024, to provide a more comprehensive view of its financial standing and performance.

Investors, stakeholders, and market analysts eagerly await Sarepta Therapeutics’ complete financial results to gain a more in-depth understanding of the Company’s financial health and trajectory moving forward.

This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For additional information, read Sarepta Therapeutics’s 8K filing here.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.